Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 16/20 | 1.00 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4589246 | 1.00 | SLC6A9 (1.00) | SLC6A9CTSSCTSK | |
| SCHEMBL1689516 | 1.00 | SLC6A9 (1.00) | SLC6A9CTSSCTSK | |
| Hydrochloric Acid SCHEMBL4588821 | 0.99 | SLC6A9 (0.98) | SLC6A9CTSSCTSK | |
| Hydrochloric Acid SCHEMBL4588987 | 0.99 | SLC6A9 (0.98) | SLC6A9CTSSCTSK | |
| Hydrochloric Acid SCHEMBL4588992 | 0.99 | SLC6A9 (0.98) | SLC6A9CTSSCTSK | |
| SCHEMBL8220931 | 0.94 | SLC6A9 (0.89) | SLC6A9CTSSCTSK | |
| SCHEMBL8225808 | 0.93 | SLC6A9 (0.86) | SLC6A9CTSSCTSK | |
| SCHEMBL8213192 | 0.87 | SLC6A9 (0.77) | SLC6A9CTSSCTSK | |
| SCHEMBL2054716 | 0.86 | SLC6A9 (0.76) | SLC6A9CTSSCTSK | |
| SCHEMBL1795282 | 0.86 | SLC6A9 (0.76) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326722-B2 | N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives, their preparation and their application in therapy | SANOFI-AVENTIS (FR) | 2008-02-05 | — | — | US | claimed |
| US-20070197601-A1 | Use of N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives in therapy | SANOFI-AVENTIS (FR) | 2007-08-23 | — | — | US | claimed |
| EP-1499589-B1 | DERIVATIVES OF N-PHENYL(PIPERIDIN-2-YL)METHYL BENZAMIDE, THE PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2007-05-02 | — | — | EP | claimed |
| US-20050159450-A1 | Derivative of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2005-07-21 | — | — | US | claimed |
| US-20240052418-A1 | METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-15 | — | — | US | disclosed |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | DISC MEDICINE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814681-B2 | Method for predicting a subjects response to SLC modulator therapy | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220313139-A1 | APPARATUSES AND METHODS FOR IDENTIFICATION AND TREATMENT OF PATIENTS RESPONSIVE TO ANTIPSYCHOTIC AGENT THERAPY | SIEKMEIER PETER J (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220313170-A1 | METHOD OF INCREASING COGNITIVE FUNCTION WITH GLUTAMATE RECEPTOR AGONIST | SIEKMEIER PETER J (US) | 2022-10-06 | — | — | US | disclosed |
| EP-4025118-A1 | APPARATUSES AND METHODS FOR IDENTIFICATION AND TREATMENT OF PATIENTS RESPONSIVE TO ANTIPSYCHOTIC AGENT THERAPY | Siekmeier, Peter J. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-4025290-A1 | METHOD OF INCREASING COGNITIVE FUNCTION WITH GLUTAMATE RECEPTOR AGONIST | Siekmeier, Peter J. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20210301038-A1 | POLYSIALIC ACID AND DERIVATIVES THEREOF, PHARMACEUTICAL COMPOSITION AND METHOD OF PRODUCING POLYSIALIC ACID | DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E.V. (DZNE) (DE) | 2021-09-30 | — | — | US | disclosed |
| US-20210283129-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | DISC MEDICINE, INC. | 2021-09-16 | — | — | US | disclosed |
| EP-3829717-A2 | POLYSIALIC ACID AND DERIVATIVES THEREOF, PHARMACEUTICAL COMPOSITION AND METHOD OF PRODUCING POLYSIALIC ACID | Medizinische Hochschule Hannover (MHH) (DE) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020025653-A2 | POLYSIALIC ACID AND DERIVATIVES THEREOF, PHARMACEUTICAL COMPOSITION AND METHOD OF PRODUCING POLYSIALIC ACID | MEDIZINISCHE HOCHSCHULE HANNOVER (MHH) (DE) | 2020-02-06 | — | — | WO | disclosed |
| US-20150141462-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING DRUG ADDICTION AND PREVENTING A DRUG RELAPSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-21 | — | — | US | disclosed |
| WO-2013188465-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING DRUG ADDICTION AND PREVENTING A DRUG RELAPSE | ARIZONA BOARD OF REGENTS, FOR AND ON BEHALF OF, ARIZONA STATE UNIVERSITY (US) | 2013-12-19 | — | — | WO | disclosed |
| EP-1499589-B1 | DERIVATIVES OF N-PHENYL(PIPERIDIN-2-YL)METHYL BENZAMIDE, THE PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2007-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210301038-A1 | POLYSIALIC ACID AND DERIVATIVES THEREOF, PHARMACEUTICAL COMPOSITION AND METHOD OF PRODUCING POLYSIALIC ACID | NEU2, NEU1, NEU3 | SLC6A9 575/4885CTSS 1854/4885CTSK 2701/4885 |
| US-20070197601-A1 | Use of N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives in therapy | SLC1A2, SLC1A1, SLC1A5 | SLC6A9 53/4885CTSS 3102/4885CTSK 3396/4885 |
| US-20050159450-A1 | Derivative of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics | NPR3, NR4A3, PRMT3 | SLC6A9 4691/4885CTSS 3277/4885CTSK 3834/4885 |
| US-20210283129-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | GFPT1, MPST, XPNPEP1 | SLC6A9 19/4885CTSS 1582/4885CTSK 2566/4885 |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | GFPT1, MPST, XPNPEP1 | SLC6A9 19/4885CTSS 1582/4885CTSK 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.